Novartis' Remibrutinib Gains FDA Approval for Chronic Spontaneous Urticaria
TL;DR Summary
Novartis received FDA approval for Rhapsido (remibrutinib), the first oral BTK inhibitor for treating adult patients with chronic spontaneous urticaria (CSU) who remain symptomatic despite antihistamines, offering a new, fast-acting, and safe treatment option without the need for injections or lab monitoring.
Topics:business#chronic-spontaneous-urticaria#fda-approval#healthcare#novartis#remibrutinib#rhapsido
- Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU) Novartis
- FDA approves Novartis’ BTK inhibitor for chronic hives Endpoints News
- Novartis' skin disease drug gets US approval Reuters
- Downtown Helena turns pink for Breast Cancer Awareness Month Yahoo
- Discussing Remibrutinib Following FDA Approval for CSU, With Adam Friedman, MD HCPLive
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
8 min
vs 8 min read
Condensed
97%
1,578 → 42 words
Want the full story? Read the original article
Read on Novartis